Abstract
Cannabinoids (natural, endogenous and synthetic compounds) produce vasorelaxation in resistance and conduit arteries. Several putative mechanisms have been proposed to explain this effect of cannabinoids. The aim of the present review is to discuss the different mechanisms involved in the vasorelaxant effect of endogenous and synthetic cannabinoids in resistance and conduit arteries. Research on the vascular effects of cannabinoids suggests that the magnitude of the vasorelaxation and the mechanisms involved are not identical in all vascular beds with one or two mechanisms predominating. Either extracellular or intracellular mechanisms are involved. With regard to the former, the stimulation of cannabinoid CB1, CB2 or nonCB1/nonCB2 cannabinoid receptors and the stimulation of vanilloid receptors, transient potential vanilloid receptors, on perivascular nerve endings with the subsequent release of the vasodilator neurotransmitter calcitonin gene-related peptide have been described. With regard to the latter, the main mechanisms implicated include nitric oxide release, metabolism to vasoactive arachidonic metabolites or prostanoid analogues, or endothelium derived hyperpolarising factor release. The knowledge of these mechanisms is crucial to identify new therapeutic targets and to understand the consequences in different vascular beds.
Keywords: Cannabinoids, blood vessels, vasorelaxation, mechanisms
Current Vascular Pharmacology
Title: Vasorelaxation Caused by Cannabinoids: Mechanisms in Different Vascular Beds
Volume: 6 Issue: 4
Author(s): Visitacion Lopez-Miranda, Esperanza Herradon and M Isabel Martin
Affiliation:
Keywords: Cannabinoids, blood vessels, vasorelaxation, mechanisms
Abstract: Cannabinoids (natural, endogenous and synthetic compounds) produce vasorelaxation in resistance and conduit arteries. Several putative mechanisms have been proposed to explain this effect of cannabinoids. The aim of the present review is to discuss the different mechanisms involved in the vasorelaxant effect of endogenous and synthetic cannabinoids in resistance and conduit arteries. Research on the vascular effects of cannabinoids suggests that the magnitude of the vasorelaxation and the mechanisms involved are not identical in all vascular beds with one or two mechanisms predominating. Either extracellular or intracellular mechanisms are involved. With regard to the former, the stimulation of cannabinoid CB1, CB2 or nonCB1/nonCB2 cannabinoid receptors and the stimulation of vanilloid receptors, transient potential vanilloid receptors, on perivascular nerve endings with the subsequent release of the vasodilator neurotransmitter calcitonin gene-related peptide have been described. With regard to the latter, the main mechanisms implicated include nitric oxide release, metabolism to vasoactive arachidonic metabolites or prostanoid analogues, or endothelium derived hyperpolarising factor release. The knowledge of these mechanisms is crucial to identify new therapeutic targets and to understand the consequences in different vascular beds.
Export Options
About this article
Cite this article as:
Lopez-Miranda Visitacion, Herradon Esperanza and Martin Isabel M, Vasorelaxation Caused by Cannabinoids: Mechanisms in Different Vascular Beds, Current Vascular Pharmacology 2008; 6 (4) . https://dx.doi.org/10.2174/157016108785909706
DOI https://dx.doi.org/10.2174/157016108785909706 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Jatrorrhizine Protects Against Okadaic Acid Induced Oxidative Toxicity Through Inhibiting the Mitogen-Activated Protein Kinases Pathways in HT22 Hippocampal Neurons
CNS & Neurological Disorders - Drug Targets Strategies for Non-Invasive Molecular Imaging of Acute Allograft Rejection by Gamma Scintigraphy and Positron Emission Tomography
Current Radiopharmaceuticals Iron Involvement in Multiple Signaling Pathways of Atherosclerosis: A Revisited Hypothesis
Current Medicinal Chemistry The Role of a Human Hematopoietic Mesenchymal Progenitor in Wound Healing and Fibrotic Diseases and Implications for Therapy
Current Stem Cell Research & Therapy Soluble Amyloid-β Levels and Late-Life Depression
Current Pharmaceutical Design The Synthesis of Coenzyme Q10
Current Organic Chemistry Blood Pressure and Vascular Alterations with Growth in Childhood
Current Pharmaceutical Design Stable Angina Pectoris: Current Medical Treatment
Current Pharmaceutical Design NAD+ Metabolism and NAD+-Dependent Enzymes: Promising Therapeutic Targets for Neurological Diseases
Current Drug Targets Societal and Cultural Attitudes to Gout: An Important Consideration in the Successful Management of Gout among Maori in Aotearoa New Zealand
Current Rheumatology Reviews Untargeted Metabolomics in the Discovery of Novel Biomarkers and Therapeutic Targets for Atherosclerotic Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
Current Pharmaceutical Design Cardiovascular Effects of Phosphodiesterase 5 Inhibitors
Current Pharmaceutical Design Subject Index to Volume 2
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Potential Usefulness of Clopidogrel Pharmacogenetics in Ce rebral Endovascular Procedures and Carotid Artery Stenting
Current Clinical Pharmacology Directions for Enhancement of the Therapeutic Efficacy of Mesenchymal Stem Cells in Different Neurodegenerative and Cardiovascular Diseases: Current Status and Future Perspectives
Current Stem Cell Research & Therapy Antioxidant Nanoparticles for Control of Infectious Disease
Infectious Disorders - Drug Targets Cannabinoids and Myocardial Ischemia: Novel insights, Updated Mechanisms, and Implications for Myocardial Infarction
Current Medicinal Chemistry Matrix Metalloproteinases: Drug Targets for Myocardial Infarction
Current Drug Targets Updated Role of Nitric Oxide in Disorders of Erythrocyte Function
Cardiovascular & Hematological Disorders-Drug Targets